Selecta Biosciences, Inc.
(NASDAQ : SELB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 0.71%579.812.7%$671.17m
AMGNAmgen, Inc. -0.36%227.161.3%$582.50m
GILDGilead Sciences, Inc. 0.20%60.791.0%$581.98m
VRTXVertex Pharmaceuticals, Inc. 0.71%211.581.9%$512.07m
ILMNIllumina, Inc. -0.73%323.553.5%$494.75m
MRNAModerna, Inc. -0.44%70.530.0%$473.04m
ARRYArray BioPharma Inc. -4.42%42.0014.2%$403.84m
IMMUImmunomedics, Inc. 0.00%87.8611.0%$392.45m
NVAXNovavax, Inc. -0.49%93.1396.5%$309.58m
ALXNAlexion Pharmaceuticals, Inc. 1.62%121.612.0%$277.29m
BIIBBiogen, Inc. -0.68%265.001.7%$264.24m
EXASEXACT Sciences Corp. 2.44%109.7020.7%$241.86m
BNTXBioNTech SE 2.70%88.690.0%$221.27m
SRNESorrento Therapeutics, Inc. -2.42%8.081.4%$162.95m
SGENSeagen Inc. -1.86%196.926.0%$157.61m

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.